Menisy

Betahistine Dihydrochloride, the active ingredient in Menisy, is a histamine analog (H1 agonist / H3 antagonist) presented as an oral tablet for oral use. It is employed to manage vestibular disorders such as Meniere’s disease, vertigo and other balance disturbances in adults.

GNH USA supplies Menisy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Betahistine Dihydrochloride is used in the management of inner‑ear disorders that affect balance and hearing. - Meniere's disease: helps reduce the frequency and severity of vertigo attacks and may improve hearing stability. - Vertigo: alleviates episodes of dizziness associated with vestibular dysfunction. - Balance disorders: supports microcirculation in the inner ear to lessen imbalance symptoms.

Betahistine Dihydrochloride is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Gastric discomfort: mild abdominal pain or dyspepsia. - Dizziness: transient light‑headedness. - Skin flushing: temporary reddening of the face or neck.

Serious or Rare Side Effects: - Rash or urticaria: signs of possible allergic reaction. - Hypotension: marked drop in blood pressure causing faintness. - Palpitations: irregular heartbeats. - Severe gastrointestinal bleeding: rare but requires immediate attention.

Before initiating therapy, consider the following safety measures. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: discuss potential risks with a physician. - Renal impairment: dose adjustment may be needed in severe cases. - Concomitant antihistamines: may blunt therapeutic effect. - Elderly patients: monitor for increased sensitivity to side effects. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Betahistine Dihydrochloride may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong antihistamines (e.g., diphenhydramine): may reduce therapeutic benefit. - Monoamine oxidase inhibitors (MAOIs): potential for exaggerated vasodilatory response.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood pressure‑lowering effect. - Diuretics: may increase risk of electrolyte imbalance. - CYP450 substrates: monitor if co‑administered with drugs metabolized by the same pathway, although betahistine has minimal CYP involvement.